US Hospitals Import Every Medical Isotope; Oklo’s Reactor Just Went Critical
Oklo Inc. said its Groves Isotope Test Reactor in Lockhart, Texas reached “first criticality” on Aug. 5, 2026 at 9:19 p.m. ET. The reactor is designed to produce medical and defense radioisotopes, including technetium-99m via molybdenum-99, to address US dependence on aging foreign reactors. The article cites a 2024 Mo-99 shortage.
How this was made
The 30-second read
Why it matters
Groves reaching first criticality is presented as a de-risking step for a reactor specifically designed for isotope production, potentially improving the probability of future domestic supply and reducing supply-chain fragility.
Market read
A concrete operational milestone for a US isotope-focused reactor can re-rate development progress, but traders should watch for follow-on commercialization and regulatory milestones.
What to watch
Key next steps are target irradiation performance, radiochemical yield/purity, hot-cell processing throughput, and securing offtake agreements with radiopharmacies and defense customers.
Background
The article frames US technetium-99m and broader medical radioisotope supply as dependent on foreign molybdenum-99 production, with prior shortages and aging reactor retirements driving a push for domestic capacity.
Ticker impact
Oklo’s Groves Isotope Test Reactor achieved nuclear first criticality on Aug. 5, 2026, validating a privately sited reactor for isotope production.
Near-term upside bias on de-risking and progress toward commercialization, with volatility tied to subsequent licensing, output, and customer qualification milestones.
The article reports a concrete, time-stamped operational milestone (first criticality) and emphasizes Groves’ isotope-production design, which is directly relevant to Oklo’s core thesis. However, it does not provide commercialization timelines, contracts, or financial guidance, limiting immediate earnings impact visibility.
Market effects
Highlights a potential domestic supply expansion for Mo-99 and related medical radioisotopes, which could shift perceived supply-chain risk for radiopharma inputs.
Texas-based reactor milestone may increase attention on US isotope production capacity and related permitting and supply-chain ecosystems.
If replicated, privately built pool-reactor isotope production could reduce reliance on aging European and Canadian reactor supply.
Counterpoint
First criticality does not guarantee reliable isotope output, regulatory approvals for commercial production, or near-term revenue, so the market may overprice the milestone.
Key entities
- companyOklo Inc.
Operator of the Groves Isotope Test Reactor that achieved nuclear first criticality on Aug. 5, 2026.
- facilityGroves Isotope Test Reactor
Pool-type, water-cooled, non-pressurized reactor designed to validate isotope production processes in the US.
- government_programDepartment of Energy Reactor Pilot Program
Program under which multiple reactors achieved criticality, with Groves described as the first privately financed, privately sited isotope-focused reactor.
